Form 4: Sanara MedTech Director Keith Myers Receives Restricted Stock Grant

Sanara MedTech Inc. Director Keith G. Myers was granted 2,965 shares of restricted common stock as part of the company's 2024 Omnibus Long-Term Incentive Plan.

Summary

• Keith G. Myers, a Director of Sanara MedTech Inc. (SMTI), acquired 2,965 shares of common stock on May 22, 2025.
• The acquisition was a grant of restricted stock under the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan, with a transaction price of $0 per share.
• These restricted shares will vest on the earlier of the 2026 annual shareholder meeting or May 22, 2026, contingent upon Mr. Myers continuing to provide services to the company.
• Following this transaction, Mr. Myers beneficially owns a total of 4,940 shares of Sanara MedTech Inc. common stock.

Sentiment

Score: 7

Explanation: The sentiment is positive as the transaction represents a standard equity compensation grant to a director, aligning their interests with shareholders and indicating continued commitment to the company. It is a routine event and does not suggest any underlying issues.

Positives

• The grant of restricted stock aligns the interests of Director Keith G. Myers with those of the shareholders, as the value of his compensation is tied to the company's stock performance.
• The transaction is part of a pre-approved long-term incentive plan, indicating a structured approach to executive and director compensation.

Risks

• The vesting of the restricted stock is conditional upon Keith G. Myers continuing to provide services to Sanara MedTech Inc. through the specified vesting dates (earlier of 2026 annual shareholder meeting or May 22, 2026).

Future Outlook

The restricted stock grant is designed to incentivize continued service from Director Keith G. Myers, with vesting contingent on his ongoing contributions to the company through at least May 22, 2026, or the 2026 annual shareholder meeting.

Management Comments

• The restricted stock grant was made pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan, reflecting the company's established compensation framework.

Industry Context

The granting of restricted stock to directors is a common practice across industries, particularly in the healthcare and medical technology sectors, to align leadership incentives with long-term shareholder value creation and ensure retention of key personnel.

Comparison to Industry Standards

• The use of restricted stock grants as a component of director compensation is a standard practice, comparable to compensation structures observed in other publicly traded medical technology companies like Integra LifeSciences Holdings Corporation or Organogenesis Holdings Inc., which also utilize equity-based incentives to align director interests with company performance.
• The vesting schedule, tied to continued service and a future date/event, is typical for such grants, ensuring retention and commitment from the director.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the value of the restricted stock is directly tied to the company's stock performance.
• Employees: While not directly impacting all employees, such grants are part of a broader compensation philosophy that can influence overall morale and retention of key personnel.

Next Steps

• The restricted shares granted to Keith G. Myers will vest on the earlier of the 2026 annual shareholder meeting or May 22, 2026, provided he continues to provide services to the company.

Key Dates

Keywords

Sanara MedTech Inc., SMTI, Form 4, Insider Transaction, Restricted Stock Grant, Director Compensation, Equity Incentive Plan, Keith G. Myers